Insiders · NBSE

Symetryx Corp

Company, not a person

Files as insider at NeuBase Therapeutics, Inc. (NBSE) since August 2023

Symetryx Corp is a company, not a person, and it has filed 6 insider reports with the SEC since September 2023, as insider at NeuBase Therapeutics, Inc. (NBSE). Symetryx Corp made no open-market purchases or sales in the last 12 months. The latest filing, on September 21, 2023, reports other acquisition or disposition at NeuBase Therapeutics, Inc. (NBSE).

Filings
6
Companies
1
Bought on market
$59.7K
Sold on market
$712K

Companies where Symetryx Corp is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
NeuBase Therapeutics, Inc. logo
NBSE
NeuBase Therapeutics, Inc.
Insidersince August 2023192,481$59.7K$712K$0.98Sep 21, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Questions about Symetryx Corp

How many shares does Symetryx Corp own?
After the latest filing that states it, Symetryx Corp directly owned 192,481 shares of NeuBase Therapeutics, Inc. (NBSE). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Symetryx Corp bought or sold stock recently?
The most recent open-market purchase was on September 1, 2023: bought 61,076 shares of NeuBase Therapeutics, Inc. (NBSE) for $59.7K at an average of $0.98. The most recent open-market sale was on September 18, 2023: sold 282,445 shares of NeuBase Therapeutics, Inc. (NBSE) for $376K at an average of $1.33.
How do I get alerts when Symetryx Corp files?
Follow Symetryx Corp on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Symetryx Corp (SEC CIK 0001991925). Totals count each trade once, skipping amendments whose original is on file, from Sep 1, 2023 on. View on SEC EDGAR